company background image
A235980 logo

MedPacto KOSDAQ:A235980 Stock Report

Last Price

₩8.25k

Market Cap

₩277.0b

7D

1.7%

1Y

-42.5%

Updated

18 Jul, 2024

Data

Company Financials

A235980 Stock Overview

A drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea.

A235980 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MedPacto, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MedPacto
Historical stock prices
Current Share Price₩8,250.00
52 Week High₩17,240.00
52 Week Low₩6,110.00
Beta0.80
11 Month Change1.98%
3 Month Change-10.42%
1 Year Change-42.51%
33 Year Change-87.83%
5 Year Changen/a
Change since IPO-54.04%

Recent News & Updates

MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans

Mar 28
MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans

Recent updates

MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans

Mar 28
MedPacto (KOSDAQ:235980) Is In A Good Position To Deliver On Growth Plans

We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business Growth

Jan 05
We Think MedPacto (KOSDAQ:235980) Can Afford To Drive Business Growth

Shareholder Returns

A235980KR BiotechsKR Market
7D1.7%2.7%-1.2%
1Y-42.5%29.4%6.0%

Return vs Industry: A235980 underperformed the KR Biotechs industry which returned 29.4% over the past year.

Return vs Market: A235980 underperformed the KR Market which returned 6% over the past year.

Price Volatility

Is A235980's price volatile compared to industry and market?
A235980 volatility
A235980 Average Weekly Movement7.5%
Biotechs Industry Average Movement7.9%
Market Average Movement4.9%
10% most volatile stocks in KR Market11.1%
10% least volatile stocks in KR Market2.2%

Stable Share Price: A235980's share price has been volatile over the past 3 months.

Volatility Over Time: A235980's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a62Seong-Jin Kimwww.medpacto.com

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

MedPacto, Inc. Fundamentals Summary

How do MedPacto's earnings and revenue compare to its market cap?
A235980 fundamental statistics
Market cap₩277.04b
Earnings (TTM)-₩30.63b
Revenue (TTM)n/a

0.0x

P/S Ratio

-9.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A235980 income statement (TTM)
Revenue₩0
Cost of Revenue₩0
Gross Profit₩0
Other Expenses₩30.63b
Earnings-₩30.63b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-912.20
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did A235980 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.